612:
214:
for $ 180 million in stock, the equivalent of $ 4.78 per share. In
December 2004, Virologic completed its acquisition of Aclara for $ 160 million in stock; each of Aclara's shareholders received 1.7 shares of Virologic stock for each share of Aclara stock they had owned.
682:
692:
581:
712:
202:
in regard to the latter company's microfluidics technology. This suit represented one of several legal battles between the two companies, each of which accused the other of
707:
672:
653:
702:
677:
697:
368:
727:
646:
531:
722:
474:
401:
717:
639:
507:
557:
179:
92:
582:"ACLARA and GlaxoSmithKline Evaluating eTag(TM) Technology for Patient Selection for Targeted Cancer Therapies"
320:
291:
267:
206:. On October 26, 2000, a jury in California found Aclara guilty of misappropriating trade secrets and awarded
187:
223:
Aclara received 96 patents during its history. Its best-known product was its proprietary eTag (short for "
178:, and was renamed Aclara Biosciences, Inc. in 1998. The company subsequently relocated its headquarters to
687:
195:
203:
456:
151:
143:
25:
344:
619:
482:
448:
376:
438:
247:
240:
224:
623:
191:
666:
147:
102:
460:
236:
199:
183:
96:
486:
452:
380:
532:"Aclara Patents Use of eTag Technology for Cell Surface Protein Measurement"
211:
81:
210:$ 52,568,000. In 2004, it was reported that Aclara would be purchased by
207:
175:
232:
244:
155:
299:
611:
443:
426:
228:
116:
618:
This article about a corporation or company specializing in
239:. In October 2004, Aclara entered into an arrangement with
369:"Convertible Debt And Equity Offerings Expected This Week"
627:
402:"Aclara, Caliper Snipe Away as Market Caps Dwindle"
123:
109:
87:
77:
69:
54:
39:
31:
21:
683:Medical technology companies of the United States
194:in March 2000. Also in 2000, Aclara was sued by
146:company, focused on developing applications of
647:
190:of 9 million shares took place on the NASDAQ
8:
693:Companies based in Mountain View, California
16:
713:Biotechnology companies established in 1995
654:
640:
243:to test these assays for potential use in
170:Aclara Biosciences was founded in 1995 as
15:
442:
198:for allegedly misappropriating Caliper's
708:Companies formerly listed on the Nasdaq
259:
673:American companies established in 1995
475:"ViroLogic to Buy Aclara BioSciences"
7:
703:2004 disestablishments in California
608:
606:
268:"ACLARA BioSciences, Inc. Form 10-Q"
508:"Virologic buys Aclara Biosciences"
321:"ACLARA BIOSCIENCES INC (ACLA) IPO"
558:"Bridging Genomics and Proteomics"
556:Fitzgerald, Deborah (2002-07-22).
272:Securities and Exchange Commission
14:
678:Companies disestablished in 2004
610:
425:Bouchie, Aaron (December 2000).
698:1995 establishments in Delaware
231:technology designed for use on
506:Gilcrest, Laura (2004-12-10).
481:. Bloomberg News. 2004-06-02.
1:
400:Hamilton, Dane (2000-10-11).
626:. You can help Knowledge by
154:. It was publicly traded on
728:Technological company stubs
204:infringing on their patents
58:December 10, 2004
744:
605:
723:Medical technology stubs
136:Aclara Biosciences, Inc.
188:initial public offering
172:Soane BioSciences, Inc.
718:Medical company stubs
427:"Aclara found guilty"
43:May 5, 1995
431:Nature Biotechnology
345:"Aclara Biosciences"
196:Caliper Technologies
129:>170 (2003)
125:Number of employees
18:
479:The New York Times
373:The New York Times
152:laboratory testing
144:medical technology
140:ACLARA Biosciences
138:(also stylized as
35:Soane Technologies
26:Medical technology
17:Aclara Biosciences
635:
634:
620:health technology
158:under the symbol
133:
132:
735:
656:
649:
642:
614:
607:
597:
596:
594:
593:
578:
572:
571:
569:
568:
553:
547:
546:
544:
543:
528:
522:
521:
519:
518:
503:
497:
496:
494:
493:
471:
465:
464:
446:
422:
416:
415:
413:
412:
397:
391:
390:
388:
387:
365:
359:
358:
356:
355:
349:Silicon Investor
341:
335:
334:
332:
331:
317:
311:
310:
308:
307:
298:. Archived from
288:
282:
281:
279:
278:
264:
248:drug development
115:Thomas Klopack (
65:
63:
50:
48:
19:
743:
742:
738:
737:
736:
734:
733:
732:
663:
662:
661:
660:
603:
601:
600:
591:
589:
580:
579:
575:
566:
564:
555:
554:
550:
541:
539:
530:
529:
525:
516:
514:
505:
504:
500:
491:
489:
473:
472:
468:
424:
423:
419:
410:
408:
399:
398:
394:
385:
383:
367:
366:
362:
353:
351:
343:
342:
338:
329:
327:
319:
318:
314:
305:
303:
290:
289:
285:
276:
274:
266:
265:
261:
256:
241:GlaxoSmithKline
225:electrophoretic
221:
168:
126:
112:
105:
99:
61:
59:
46:
44:
12:
11:
5:
741:
739:
731:
730:
725:
720:
715:
710:
705:
700:
695:
690:
685:
680:
675:
665:
664:
659:
658:
651:
644:
636:
633:
632:
615:
599:
598:
573:
548:
523:
498:
466:
417:
392:
375:. 2000-03-20.
360:
336:
312:
292:"Company Info"
283:
258:
257:
255:
252:
220:
217:
192:stock exchange
167:
164:
131:
130:
127:
124:
121:
120:
113:
110:
107:
106:
101:
91:
89:
85:
84:
79:
75:
74:
71:
67:
66:
56:
52:
51:
41:
37:
36:
33:
29:
28:
23:
13:
10:
9:
6:
4:
3:
2:
740:
729:
726:
724:
721:
719:
716:
714:
711:
709:
706:
704:
701:
699:
696:
694:
691:
689:
688:Microfluidics
686:
684:
681:
679:
676:
674:
671:
670:
668:
657:
652:
650:
645:
643:
638:
637:
631:
629:
625:
621:
616:
613:
609:
604:
587:
583:
577:
574:
563:
562:The Scientist
559:
552:
549:
537:
533:
527:
524:
513:
509:
502:
499:
488:
484:
480:
476:
470:
467:
462:
458:
454:
450:
445:
444:10.1038/82267
440:
436:
432:
428:
421:
418:
407:
403:
396:
393:
382:
378:
374:
370:
364:
361:
350:
346:
340:
337:
326:
322:
316:
313:
302:on 2003-02-02
301:
297:
293:
287:
284:
273:
269:
263:
260:
253:
251:
249:
246:
242:
238:
237:nucleic acids
234:
230:
226:
218:
216:
213:
209:
205:
201:
200:trade secrets
197:
193:
189:
185:
181:
180:Mountain View
177:
173:
165:
163:
161:
157:
153:
149:
148:microfluidics
145:
141:
137:
128:
122:
118:
114:
108:
104:
103:United States
98:
94:
93:Mountain View
90:
86:
83:
80:
76:
72:
68:
57:
53:
42:
38:
34:
30:
27:
24:
20:
628:expanding it
617:
602:
590:. Retrieved
588:. 2004-10-05
585:
576:
565:. Retrieved
561:
551:
540:. Retrieved
538:. 2003-10-07
535:
526:
515:. Retrieved
511:
501:
490:. Retrieved
478:
469:
437:(12): 1229.
434:
430:
420:
409:. Retrieved
405:
395:
384:. Retrieved
372:
363:
352:. Retrieved
348:
339:
328:. Retrieved
324:
315:
304:. Retrieved
300:the original
295:
286:
275:. Retrieved
271:
262:
222:
171:
169:
159:
139:
135:
134:
88:Headquarters
512:MarketWatch
150:for use in
32:Predecessor
667:Categories
592:2019-04-22
567:2019-04-23
542:2019-04-22
517:2019-04-22
492:2019-04-22
411:2019-04-23
386:2019-04-23
354:2019-04-22
330:2019-04-22
306:2019-04-22
277:2019-04-22
254:References
186:, and its
184:California
111:Key people
97:California
62:2004-12-10
47:1995-05-05
536:GenomeWeb
487:0362-4331
453:1087-0156
406:TheStreet
381:0362-4331
212:Virologic
82:Virologic
78:Successor
586:BioSpace
461:35293731
233:proteins
219:Products
176:Delaware
142:) was a
22:Industry
208:Caliper
166:History
73:Defunct
60: (
55:Defunct
45: (
40:Founded
485:
459:
451:
379:
325:NASDAQ
296:Aclara
245:cancer
227:tag")
156:NASDAQ
622:is a
457:S2CID
229:assay
624:stub
483:ISSN
449:ISSN
377:ISSN
235:and
160:ACLA
70:Fate
439:doi
174:in
117:CEO
669::
584:.
560:.
534:.
510:.
477:.
455:.
447:.
435:18
433:.
429:.
404:.
371:.
347:.
323:.
294:.
270:.
250:.
182:,
162:.
100:,
95:,
655:e
648:t
641:v
630:.
595:.
570:.
545:.
520:.
495:.
463:.
441::
414:.
389:.
357:.
333:.
309:.
280:.
119:)
64:)
49:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.